| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.2 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.07 | 0.2 |